IR@PKUHSC  > 北京大学第三临床医学院  > 肿瘤放疗科
学科主题临床医学
Dosimetric Study of Cs-131, I-125, and Pd-103 Seeds for Permanent Prostate Brachytherapy
Yang, Ruijie1; Wang, Junjie1; Zhang, Hongzhi2
关键词Prostate Neoplasms/brachytherapy Permanent Implant Dosimetry Cesium-131 Iodine-125 Polodium-103
刊名CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
2009-12-01
DOI10.1089/cbr.2009.0648
24期:6页:701-705
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Medicine, Research & Experimental ; Pharmacology & Pharmacy ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]Oncology ; Research & Experimental Medicine ; Pharmacology & Pharmacy ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]POSTIMPLANT DOSIMETRY ; CANCER ; IMPLANTS ; OUTCOMES ; EDEMA ; ALPHA/BETA ; ISOTOPE ; IMPACT ; MODEL ; TRIAL
英文摘要

As a well-established single-modality approach for early-stage prostate cancer, transperineal interstitial permanent prostate brachytherapy (TIPPB) has gained increasing popularity due to its favorable clinical results. Currently, three isotopes, namely Cs-131, I-125, and Pd-103, are commercially available for TIPPB. This is the first study to systematically explore the dosimetric difference of these three isotopes for TIPPB. In total, 25 patients with T1-T2c prostate cancer previously implanted with I-125 seeds were randomly selected and replanned with Cs-131, I-125, and Pd-103 seeds to the prescription doses of 115, 145, and 125 Gy, respectively. The planning goals attempted were prostate V(p)100 similar to 95%, D(p)90 >= 100%, and prostatic urethra D(u)10 <= 150%. The dosimetric parameters, as well as the number of seeds and needles required, were analyzed and compared. The mean homogeneity index (HI) was 0.59, 0.56, and 0.46 for Cs-131, I-125, and Pd-103 plans, respectively. The average D(u)10 was 124.6%, 125.7%, and 129.7%, respectively. The average rectum V(r)100 was 0.19, 0.22, and 0.31 cc, respectively. In addition, the average number of seeds was 57.9, 63.0, and 63.7, and the average number of needles required was 31.6, 32.9, and 33.6 for Cs-131, I-125, and Pd-103 seeds, respectively. This study demonstrates that TIPPB, utilizing Cs-131 seeds, allows for better dose homogeneity, while providing comparable prostate coverage and sparing of the urethra and rectum, with a comparable number of, or fewer, seeds and needles required, compared to I-125 or Pd-103 seeds. Further biological and clinical studies associated with Cs-131 are warranted.

语种英语
WOS记录号WOS:000272955600008
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52435
专题北京大学第三临床医学院_肿瘤放疗科
作者单位1.Peking Univ, Dept Radiat Oncol, Ctr Canc, Hosp 3, Beijing 100191, Peoples R China
2.Peking Union Med Coll, Chinese Acad Med Sci, Canc Inst Hosp, Dept Radiat Oncol, Beijing 100021, Peoples R China
推荐引用方式
GB/T 7714
Yang, Ruijie,Wang, Junjie,Zhang, Hongzhi. Dosimetric Study of Cs-131, I-125, and Pd-103 Seeds for Permanent Prostate Brachytherapy[J]. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,2009,24(6):701-705.
APA Yang, Ruijie,Wang, Junjie,&Zhang, Hongzhi.(2009).Dosimetric Study of Cs-131, I-125, and Pd-103 Seeds for Permanent Prostate Brachytherapy.CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS,24(6),701-705.
MLA Yang, Ruijie,et al."Dosimetric Study of Cs-131, I-125, and Pd-103 Seeds for Permanent Prostate Brachytherapy".CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS 24.6(2009):701-705.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Yang, Ruijie]的文章
[Wang, Junjie]的文章
[Zhang, Hongzhi]的文章
百度学术
百度学术中相似的文章
[Yang, Ruijie]的文章
[Wang, Junjie]的文章
[Zhang, Hongzhi]的文章
必应学术
必应学术中相似的文章
[Yang, Ruijie]的文章
[Wang, Junjie]的文章
[Zhang, Hongzhi]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。